A-1331852 manufacturers
- A-1331852
-
- $47.00
-
2026-07-27
- CAS:1430844-80-6
- Purity: 99.50%
- Supply Ability: 10g
|
| | A-1331852 Basic information |
| Product Name: | A-1331852 | | Synonyms: | A-1331852;6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-(adamantylmethyl)-5-methyl-1H-pyrazol-4-yl)picolinic acid;CS-2498;A 1331852;A1331852;6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]pyridine-2-carboxylic acid;2-Pyridinecarboxylic acid, 6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-;3-(1-(Adamantan-1-ylmethyl)-5-methyl-1H-pyrazol-4-yl)-6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)picolinic acid;A-1331852,Inhibitor,inhibit,A1331852,Bcl-2 Family,A 1331852 | | CAS: | 1430844-80-6 | | MF: | C38H38N6O3S | | MW: | 658.81 | | EINECS: | | | Product Categories: | A-1331852 | | Mol File: | 1430844-80-6.mol |  |
| | A-1331852 Chemical Properties |
| Melting point | >161oC (dec.) | | density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | Acetonitrile (Slightly, Heated), DMSO (Slightly) | | pka | 8.88±0.70(Predicted) | | form | Solid | | color | Pale Yellow to Light Beige | | InChIKey | QCQQONWEDCOTBV-UHFFFAOYSA-N | | SMILES | C1(C(O)=O)=NC(N2CCC3=C(C2)C(C(NC2=NC4=CC=CC=C4S2)=O)=CC=C3)=CC=C1C1=C(C)N(CC23CC4CC(CC(C4)C2)C3)N=C1 |
| | A-1331852 Usage And Synthesis |
| Description | A-1331852 is an orally bioavailable Bcl-xL inhibitor that selectively binds Bcl-xL over Bcl-2, Mcl-1, and Bcl-W (Kis = <0.01, 6, 142, and 4 nM, respectively). It inhibits growth of Bcl-xL-dependent MOLT-4, but not Bcl-2-dependent RS4;11, acute lymphocytic leukemia cells in vitro (EC50s = 6 and >5,000 nM, respectively). A-1331852 (25 mg/kg twice per day) inhibits tumor growth in a MOLT-4 mouse xenograft model. It also inhibits tumor growth and increases the antitumor activity of docetaxel in MDA-MB-231 LC3 metastatic breast cancer and NCI-H1650 non-small cell lung cancer mouse xenograft models when administered at a dose of 25 mg/kg. A-1331852 also increases venetoclax inhibition of tumor growth in an NCI-H1963.FP5 small cell lung cancer mouse xenograft model. | | Uses | A-1331852 is a substituted benzothiazole that can serve as an anti-apoptotic Bcl-xL protein inhibitor and apoptosis-inducing agent useful in the treatment of cancer, immune and autoimmune diseases. | | in vitro | a-1331852 was identified as a potent bcl-xl inhibitor demonstrating cellular activity 10- to 50-fold more potent than its analog a-1155463 and the previouly reported bcl-xl inhibitor, navitoclax, respectively. moreover, a-1331852 could selectively disrupt bcl-xl–bim complexes and induce the apoptosis hallmarks in bcl-xl–dependent molt-4 cells with median ic50 values in the low nanomolar range but did not affect mef cells without bak or bax [1]. | | in vivo | previous animal study found that a-1331852 could demonstrate antitumor efficacy in the molt-4 xenograft model, such as tumor regressions as a single agent. in addition, in the nci-h1963.fp5 xenograft model of sclc, it was found that a-1331852 combined with venetoclax was able to recapitulate the efficacy of navitoclax [1]. | | IC 50 | Bcl-xL: 0.01 nM (Ki); Bcl-W: 4 nM (Ki); Bcl-2: 6 nM (Ki); Mcl-1: 142 nM (Ki) | | storage | Store at -20°C | | references | [1] leverson jd et al. exploiting selective bcl-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. sci transl med. 2015 mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642. |
| | A-1331852 Preparation Products And Raw materials |
|